Deals
Sanofi Is Discussing Lemtrada Payments With Genzyme
This article is for subscribers only.
Sanofi-Aventis SA said takeover talks with Genzyme Corp. now involve executives from both companies as the two sides discuss extra payments tied to Lemtrada, an experimental multiple sclerosis drug.
“Significant differences” remain and there’s no guarantee a deal will be reached, Paris-based Sanofi said in an e-mailed statement yesterday. France’s biggest drugmaker on Oct. 4 made a hostile offer of $69 a share, or $18.5 billion, for Genzyme, which the U.S. company rejected as too low.